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Thirty litres of fermentation broth was extracted from the newly isolated
Streptomyces sp. strain TN17 and various separation and purification
steps led to the isolation of three pure bioactive compounds (1–3).
Compound 1: cyclo (L-Leu-L-Arg), a diketopiperazine ‘DKP’ derivative;
2: di-(2-ethylhexyl) phthalate, a phthalate derivative; and 3: cyclo
1-[2-(cyclopentanecarbonyl-3-phenyl-propionyl]-pyrrolidine-2-carboxylic
acid (1-carbamoyl-propyl)-amide, a cyclic tetrapeptide derivative. The
chemical structure of these three active compounds was established on the
basis of spectroscopic studies (MS and NMR) and by comparison with
data from the literature. According to our biological studies, the pure
compounds (1–3) possess antibacterial and antifungal activities.
Keywords: Streptomyces sp. TN17; purification; chemical structure; cyclo
(L-Leu-L-Arg); phthalate derivative; cyclic tetrapeptide
1. Introduction
The increase in the frequency of multi-resistant pathogenic bacteria has created an
urgent demand in the pharmaceutical industry for more rational approaches and
strategies in the screening of new antibiotics. Currently available bioactive molecules
can be classified in different ways based on the bacterial spectrum, the type of
activity (bactericidal or bacteriostatic) and the chemical structure. Using chemical
structure classification, several classes of antibiotics can be distinguished: -lactams,
chemically characterised by a -lactam ring; chloramphenicol, a nitro benzene
derivative of dichloroacetic acid; macrolides, macrocyclic lactones divided in two
main subgroups – polyene macrolide and non-polyenic macrolide antibiotics;
glycopeptides, which consist of glycosylated cyclic or polycyclic nonribosomal
peptides; polyethers, which contain a number of cyclic ether and ketal units and have
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a carboxylic acid group; aminoglycosides, which characteristically contain amino
sugars; tetracyclines, characterised as containing a polyhydronaphthacene nucleus;
the cyclic tetrapeptides family; diketopiperazine derivatives ‘DKP’ (piperazine 2,5-
diones, 2,5-dioxopiperazines or cyclodipeptides); phthalate derivatives; and so on.
It has been well established that microorganisms are an unlimited source
of natural products, many of which have potential therapeutic applications.
Filamentous soil bacteria belonging to the genus Streptomyces are widely recognised
as industrially important microorganisms because of their ability to produce many
kinds of secondary metabolites, including antibiotics and bioactive compounds
valued in human and veterinary medicine and agriculture (Williams et al., 1983).
These bacteria produce about 75% of commercially and medically useful antibiotics,
and approximately 60% of antibiotics which have been developed for agricultural
use were isolated from Streptomyces species (Miyadoh, 1993; Tanaka &Mura, 1993).
This genus of bacteria represents at least 90% of actinomycetes isolated from
soil (Anderson & Wellington, 2001). Active molecules of Streptomyces species
are generally extracellular, and their isolation in the highest purity from the complex
fermentation broth needs the application of a combination of various separation
steps, such as solvent extraction, chemical precipitation, ion exchange chromato-
graphy, HPLC purification, etc.
From Tunisian soil we have isolated a new actinomycete strain called
Streptomyces sp. TN17, producing diverse biological activities (data not shown).
The present article describes the extraction, purification (using different chromato-
graphic techniques) and the structure elucidation of three bioactive molecules from
a liquid culture broth of this strain. The biological activity of these pure compounds
is also addressed.
2. Results and discussion
2.1. Structure elucidation of the active compounds
2.1.1. Cyclo (L-Leu-L-Arg) (1)
Compound 1 was obtained as a yellowish UV-absorbing solid. In DMSO, the 13C
and HSQC spectra showed 11 carbon signals. From the 13C data, it was possible to
discern two carbonyl groups (c 170.8 and 167.0), three sp
3-hybridised carbons
bearing an electronegative heteroatom (c 59.0, 53.1 and 45.3), four sp
3-hybridised
carbon (c 38.3, 27.9, 24.6 and 22.9) and two methyl groups (c 23.3 and 22.4). The
2D 1H–1H and 1H–13C experiments permitted assignment of two fragments to
leucine and arginine. The presence of a NH proton (H 7.96) and observed HMBC
and NOE correlations enabled the identification of compound 1 as a (L-Leu-L-Arg)
dipeptide. Based on these data, two possible structures were suggested for this
compound. The first one is a linear structure where the corresponding molecular
weight (MW) will be 287, and the second one is a cyclic structure where the MW will
be 269 (Figure 1(a) and (b)). To distinguish between these two situations, we have
determined the mass of compound 1 using the LC/MS technique. The obtained
result, [M–H]þ¼ 268.5, shows that the corresponding MW is 269. Consequently, we
can deduce that compound 1 possesses a cyclic structure (Figure 1(b)), and the
corresponding molecular formula is C12H23O2N5.
2.1.2. Di-(2-ethylhexyl) phthalate (2)
Compound 2 was obtained as a white coloured solid. In CD2Cl2, the
13C and HSQC
spectra showed 12 carbon signals. From the 13C data, it was possible to discern one
carbonyl group (c 162.5), three sp
2-hybridised carbons (c 132.5, 130.9 and 128.7),
one sp3-hybridised carbon bearing an electronegative heteroatom (c 68.0), five
sp3-hybridised carbons (c 35.8–23.8) and two methyl groups (c 13.8 and 10.7). The
1H NMR spectrum showed a characteristic AA0BB0 system at 7.74 and 7.59 ppm
(JAA0¼ 0.7Hz, JAB¼ JA0B0¼ JBB0¼ 7.8Hz and JAB0¼ JA0B¼ 1.1Hz obtained from
simulation). These data established a compound that has a di ortho-substituted
aromatic ring. Based on the revealed spectral data and a search in AntiBase,
compound 2 was identified as di-(2-ethylhexyl) phthalate (Figure 2). The
corresponding molecular formula is C24H38O4, with a MW of 390.
2.1.3. Cyclo 1-[2-(cyclopentanecarbonyl-3-phenyl-propionyl]-pyrrolidine-
2-carboxylic acid (1-carbamoyl-propyl)-amide (3)
Compound 3 was obtained as a white coloured solid. In CD3OD, the
13C and HSQC
spectra showed 12 carbon signals. From the 13C data, it was possible to discern two
carbonyl groups (c 169.5 and 165.5), four sp
2-hybridised carbons (c from 137.7
to 126.8), three sp3-hybridised carbons bearing an electronegative heteroatom
(c 58.9, 56.2 and 45.0) and three sp
3-hybridised carbons (c 35.8, 28.2 and 22.4).
The 2D 1H–1H and 1H–13C experiments permitted assignment of two fragments to
proline and phenylalanine. The HMBC correlations from the -protons and proline
CH2-5 protons to the respective amide carbonyls established the cyclic tetrapeptide.
The structure of compound 3 was determined to be 1-[2-(cyclopentanecarbonyl-3-
phenyl-propionyl]-pyrrolidine-2-carboxylic acid (1-carbamoyl-propyl)-amide





















































Figure 2. HMBC and COSY correlations of compound 2.
2.2. Biological activities of the three characterised compounds
The new isolated Streptomyces sp. strain TN17 produced simultaneously three active
compounds belonging to three different structure types.
The first active compound (1) is the cyclo (L-Leu-L-Arg), a diketopiperazine
(DKP) derivative. DKP derivatives, produced naturally by many organisms and
microorganisms, display a very wide diversity of structures and biological functions,
making them useful chemical entities for the discovery and development of new
drugs. Useful biological properties have already been demonstrated for some of
them, such as antibacterial, fungicidal, herbicidal, antiviral, immunosuppressor,
antitumour activities, etc. (Magyar, Zhang, Abdi, Kohn, & Widger, 1999).
Several DKP derivatives have been purified and characterised, especially from
Streptomyces species (Ben Ameur-Mehdi, Mellouli, Chabchoub, Fotso, & Bejar,
2004; Ben Ameur-Mehdi, Sioud, Fourati Ben Fguira, Bejar, & Mellouli, 2006; Rhee,
2002). Compound 1 has been previously described as a natural product from
Streptomyces species (Tatsuta, Tsuchiya, Umezawa, Naganawa, & Hamao, 1972) or
obtained by chemical synthesis (Sasaki et al., 1982). According to our antimicrobial
activity studies, we have observed that compound 1 possesses antibacterial activities
against Gram-positive and Gram-negative bacteria, as well as antifungal activities
(Table 1).
The second active compound produced by the Streptomyces sp. TN17 is the
di-(2-ethylhexyl) phthalate (2). Phthalate compounds are petrochemicals used as
plasticisers or solvents in a variety of industrial products. Nevertheless, many
phthalate derivatives have been isolated from terrestrial and marine organisms,
including plants (Lee, J. Kim, Lim, & C. Kim, 2000), marine algae (Chen, 2004), and
fungal (Amade, Mallea, & Bouaicha, 1994) and bacterial culture broths, especially
those belonging to the genus Streptomyces. Compound 2 has been already described
from Streptomyces bangladeshiensis (Al-Bari, Abu Sayeed, Sazedur Rahman, &
Ashik Mossadik, 2006). Other phthalate derivatives have been isolated from
Streptomyces species, such as the dibutyl phthalate (El-Naggar, 1997; Lee, 2000;
Roy, Laskar, & Sen, 2006). Phthalate derivatives which possess several antimicrobial
activities are also effective compounds against demodicidosis (Yuan, Guo, Qin,
Deng, & Huang, 2001), as well as endocrine disruptors with estrogenic activity
(Marchetti et al., 2002) and drug channelling agents (Makhija & Vavia, 2003). Our
antimicrobial studies show that compound 2 possesses antibacterial activities against






















Figure 3. HMBC and COSY correlations of compound 3.
The third active compound (3) produced by the studied TN17 strain is the
cyclo 1-[2-(cyclopentanecarbonyl-3-phenyl-propionyl]-pyrrolidine-2-carboxylic acid
(1-carbamoyl-propyl)-amide, a cyclic tetrapeptide derivative. Cyclic tetrapeptides
are a class of natural products that have been shown to possess broad-ranging
biological activities and good pharmacokinetic properties (Horton et al., 2008).
Several groups of cyclic tetrapeptides have been described, such as rhodopeptins
isolated from Rhodococcus species having antifungal activities (Chiba, Agematu,
Dobashi, & Yoshioka, 1999), cyclic tetrapeptides group of protein synthesis
inhibitors described from Streptomyces genus (Brandi et al., 2006), and apicidin
tetrapeptides group acting as antitumour agents that can induce cell cycle arrest and
apoptosis in various cancer cells (Okada et al., 2006). Compound 3 has been isolated
from Streptomyces barakatei J2 and a patent for the use of this active molecule in
plant treatment has been deposed (Lebrihi, Errakhi, & Barakate, 2008). According to
our microbiological tests, compound 3 shows inhibitory activities against Gram-
positive bacteria and fungi (Table 1).
3. Experimental
An NMR sample was prepared by dissolving the pure compounds (1–3) in
600 mL of DMSO, CD2Cl2 and CD3OD, respectively. 1D and 2D
1H and 13C NMR
experiments were recorded on a Bruker Avance 500 spectrometer equipped with
a 5mm triple resonance inverse Z-gradient probe (TBI 1H, 31P, BB) or a Bruker
Avance 600 spectrometer equipped with a 5mm triple resonance inverse (TCI 1H,
13C, 15N) Z-gradient cryoprobe. All chemical shifts for 1H and 13C are relative to
TMS using 1H (residual) or 13C chemical shifts of the solvent as a secondary
standard. The temperature was set at 298K. All the 1H and 13C signals were assigned
on the basis of chemical shifts, spin–spin coupling constants, splitting patterns and
signal intensities, and by using 1H–1H COSY45, 1H–13C HMQC and 1H–13C HMBC
experiments.
The LC/MS analysis of compound 1 was performed using an LC/MSD Trap
XCT – Electrospray (Agilent Technologies), equipped with an HPLC Agilent 100
Table 1. Antimicrobial activities of compounds 1–3.
Diameter of inhibition zones (mm)
Test organism 1 2 3
M. luteus LB 14110 20 17 19
S. aureus ATCC 6538 14 12 15
E. coli ATCC 8739 11 ND ND
Fusarium sp. 21 14 17
Notes: A total of 50 mg per platelet, diameter of inhibition zones in mm.
ND: activity not detected. For each pure active compound and indicator
microorganism, the experiment was carried out simultaneously three times
in the same conditions. In each case, all obtained diameters of inhibition
zones were quite similar and the reported inhibition zones (mm) are the
average of the three experiments.
DAD detector (C18 column Zorbax 300 2.1 150mm). [M–H]
+ of 1 is 268.5, which
involves a corresponding MW of 269.
3.1. Microorganisms
The Streptomyces sp. TN17 strain was isolated and selected as a producer of
potent antimicrobial activities. Bacterial strains: Micrococcus luteus LB 14110,
Staphylococcus aureus ATCC 6538 and Escherichia coli ATCC 8739 were used as
indicator microorganisms for the antibacterial activity essays. Antifungal activity
was determined against the filamentous fungus, Fusarium sp.
3.2. Culture conditions and biological assays of antimicrobial activities
Indicator microorganisms were grown overnight in LB medium at 30C forM. luteus
LB14110 (Gram-positive bacteria) and at 37C for S. aureus ATCC 6538 (Gram-
positive bacteria) and E. coli ATCC 8739 (Gram-negative bacteria), then diluted
1 : 100 in LB medium and incubated for 5 h under constant agitation of 200 rpm at
the appropriate temperature. Fusarium sp. was grown in potato dextrose agar (PDA)
for 7 days at 30C. Spores were collected in sterile distilled water and then adjusted
to a spore density of approximately 104 spores Lÿ1. Antimicrobial activities were
determined by the agar diffusion test: a paper disk (8mm Ø) was impregnated
with 50 mL of the corresponding sample and then laid on the surface of an agar
plate containing 3mL of top agar inseeded by 40 mL of a 5-h-old culture of the
corresponding microorganism. For antifungal activity against Fusarium sp., 100 mL
of spores suspension were added to the 3mL of top agar. After 2 h at 4C, plates
containing M. luteus LB 14110 and Fusarium sp. were incubated at 30C and those
inoculated with S. aureus ATCC 6538 and E. coli ATCC8739 were incubated
overnight at 37C. The antimicrobial activities of the three pure compounds (1–3)
were determined under the same conditions mentioned above. The quantity used for
each pure active compound was 50 mg per disk. Plates were examined for evidence of
antimicrobial activities represented by a zone of inhibition of growth of the
corresponding indicator microorganisms around the paper disk.
3.3. Extraction and purification of active compounds
Spores at 107Lÿ1 of Streptomyces strain TN17 were used to inoculate 1000mL
Erlenmeyer flasks with four indents, containing 200mL of TSB (tryptic soy broth)
medium at 30 gLÿ1 supplemented with 1% (w/v) of glucose and potassium
phosphate at 1mmolLÿ1. After incubation at 30C for 24 h in an orbital incubator
with shaking at 200 rpm, this pre-culture was used to inoculate (5% v/v) a total
volume of 30L culture medium having the same composition of the pre-culture.
The shaker culture broth was harvested after 3 days to separate mycelium and
supernatant. The resulting supernatant was extracted two times by ethyl acetate
(v/v). The obtained organic phases were evaporated to dryness under vacuum,
to give a brown crude extract (2.8 g) which was dissolved in 5mL of dichloro-
methane–methanol (DCM/90% MeOH/10%) and then subjected to a column chro-
matography on Sephadex LH-20 using a dichloromethane–methanol (DCM/90%
MeOH/10%) giving seven fractions, which were reduced to three fractions (FI–FIII)
by monitoring of TLC.
3.3.1. Fraction FI
The biologically active fraction FI was then subjected to a series of chromato-
graphic systems: a column chromatography on silica gel eluted with a gradient of
100%DCM–0%MeOH to 0%DCM–100%MeOH. An active sub-fraction was
obtained at 85%DCM–15%MeOH. This sub-fraction was then fractioned by
HPLC (Waters: controller 600, pump 600, dual  absorption detector 2487, linear
recorder); column C18 (250 7) 8mm UP ODS). Elution was at a flow rate of
1mLminÿ1 with a linear gradient of two solutions A (water) and B (acetonitrile)
from 100% buffer A to 50% buffer A and 50% buffer B over the first 35min,
followed by a linear gradient to 100% buffer B from 35 to 45min. Detection was
carried out by using a wavelength of 280 nm. Different well-developed peaks having
a retention time between 5min and 45min were collected separately, concentrated
and then tested for the inhibitory activity against the used indicator microorganisms.
Only the compound corresponding to the peak having a retention time of 39min (1)
possessed biological activities.
Compound (1): Cyclo (L-Leu-L-Arg). 1H NMR (DMSO-d6, 600MHz)  7.96 (1H, br
s, Arg-NH),  4.19 (1H, dd, J¼ 8.1, 8.0Hz, Arg-H2),  4.01 (1H, dd, J¼ 6.9, 5.9Hz,
Leu-H2),  3.41 (1H, m, Arg-H5),  3.28 (1H, m, Arg-H5),  2.13 (1H, m, Arg-H3), 
1.92 (1H, m, Arg-H3),  1.90 (2H, m, Leu-H4),  1.79 (2H, m, Arg-H4),  1.77 (1H,
m, Leu-H3),  1.37 (1H, m, Leu-H3),  0.88 (3H, d, J¼ 7.0Hz, Leu-H5),  0.87 (3H,
d, J¼ 7.0Hz, Leu-H50); 13C NMR (DMSO-d6, 150MHz)  170.8 (C, Arg-C1),  167.0
(C, Leu-C1),  59.0 (CH, Arg-C2),  53.1 (CH, Leu-C2),  45.3 (CH2, Arg-C5),  38.3
(CH2, Leu-C3),  27.9 (CH2, Arg-C3),  24.6 (CH, Leu-C4),  23.3 (CH3, Leu-C5), 
22.9 (CH2, Arg-C4) and  22.4 (CH3, Leu-C5
0).
3.3.2. Fractions FII and FIII
These two active fractions were subjected separately to two other purification steps:
preparative thin-layer chromatography (PTLC) and HPLC fractionation, using the
conditions similar to those for compound 1 to obtain the two pure active compounds
(2 and 3) having retention times of 11.2 and 23.5min, respectively.
Compound (2): Di-(2-ethylhexyl) phthalate. 1H NMR (CD2Cl2, 500MHz)
 7.74 (1H, m, H3),  7.59 (1H, m, H4),  4.25 (1H, dd, J¼ 10.8, 5.6Hz, H10),
 4.21 (1H, dd, J¼ 10.8, 6.0Hz, H10),  1.71 (1H, m, H20),  1.46 (2H, m, H70),  1.40
(2H, m, H30),  1.36 (4H, m, H40, H50),  0.96 (3H, t, J¼ 7.3Hz, H80),  0.94
(3H, t, J¼ 7.0Hz, H60); 13C NMR (CD2Cl2, 125MHz)  162.5 (C, C1),  132.5
(C, C2),  130.9 (CH, C4),  128.7 (CH, C3),  68.0 (CH2, C1
0),  38.8 (CH, C20),
 30.4 (CH2, C3
0),  28.9 (CH2, C4
0),  23.8 (CH2, C7
0),  23.0 (CH2, C5
0),  13.8
(CH3, C6
0) and  10.7 (CH3, C8
0).
Compound (3): Cyclo 1-[2-(cyclopentanecarbonyl-3-phenyl-propionyl]-pyrro-
lidine-2-carboxylic acid (1-carbamoyl-propyl)-amide. 1HNMR (CD3OD, 500MHz)
 7.98 (1H, br s, Phe-NH),  7.27 (4H, m, Phe-H5, Phe-H6),  7.20 (1H, m, Phe-H7),
 4.36 (1H, t, J¼ 5.1Hz, Phe-H2),  4.36 (1H, dd, J¼ 9.0, 7.0Hz, Pro-H2),  3.40
(1H, m, Pro-H5), 3.28 (1H, m, Pro-H5),  3.08 (1H, dd, J¼ 14.2, 5.1Hz, Phe-H3), 3.02
(1H, dd, J¼ 14.2, 5.1Hz, Phe-H3), 2.01 (1H, m, Pro-H3), 1.73 (2H, m, Pro-H4),
1.43 (1H, m, Pro-H3); 13C NMR (CD3OD, 125MHz)  169.5 (C, Pro-C1),  165.5
(C, Phe-C1),  137.7 (C, Phe-C4),  130.2 (CH, Phe-C5),  128.4 (CH, Phe-C6),  126.8
(CH, Phe-C7),  58.9 (CH, Pro-C2),  56.2 (CH, Phe-C2),  45.0 (CH2, Pro-C5),  35.8
(CH2, Phe-C3),  c28.2 (CH2, Pro-C3) and  22.4 (CH2, Pro-C4).
Acknowledgements
This work was supported by the CMCU project No. 06/S 0901 ‘MELLOULI/AIGLE’. The
authors are grateful to Mr H. Aouissaoui and Ms L. Jlail for the LC/MS determination and
to Ms L. Elleuch and Ms M.I. Karray-Rebai for generous help.
References
Al-Bari, M.A.A., Abu Sayeed, M., Sazedur Rahman, M., & Ashik Mossadik, M. (2006).
Characterization and antimicrobial activities of a phthalic acid derivative produced by
Streptomyces bangladeshiensis, a novel species collected in Bangladesh. Research Journal
of Medicine and Medical Sciences, 1(2), 77–81.
Amade, P., Mallea, M., & Bouaicha, N. (1994). Isolation, structural identification and
biological activity of two metabolites produced by Penicillium olsonii Bainier and
Sartory. The Journal of Antibiotics, 47(2), 201–207.
Anderson, A.S., & Wellington, E.M.H. (2001). The taxonomy of Streptomyces and related
genera. International Journal of Systematic and Evolutionary Microbiology, 51(3),
797–814.
Ben Ameur-Mehdi, R., Mellouli, L., Chabchoub, F., Fotso, S., & Bejar, S. (2004). Purification
and structure elucidation of two biologically active molecules from a new isolated
Streptomyces sp. US 24 strain. Chemistry of Natural Compounds, 40(5), 510–513.
Ben Ameur-Mehdi, R., Sioud, S., Fourati Ben Fguira, L., Bejar, S., & Mellouli, L. (2006).
Purification and structure determination of four bioactive molecules from a newly
isolated Streptomyces sp. TN97 strain. Process Biochemistry, 41(7), 1506–1513.
Brandi, L., Lazzarini, A., Cavaletti, L., Abbondi, M., Corti, E., Ciciliato, I., et al. (2006).
Novel tetrapeptide inhibitors of bacterial protein synthesis produced by a Streptomyces
sp. Biochemistry, 45(11), 3692–3702.
Chen, C.Y. (2004). Biosynthesis of di-(2-ethylhexyl) phthalate (DEHP) and di-n-butyl
phthalate (DBP) from red alga – Bangia atropurpurea. Water Research, 38(4),
1014–1018.
Chiba, H., Agematu, H., Dobashi, K., & Yoshioka, T. (1999). Rhodopeptins, novel cyclic
tetrapeptides with antifungal activities from Rhodococcus sp. III. Synthetic study of
rhodopeptins. The Journal of Antibiotics, 52(8), 710–718.
El-Naggar, M.Y.M. (1997). Dibutyl phthalate and the antitumour agent F5A1, two
metabolites produced by Streptomyces nasri submutant H35. Biomedical Letters,
55(218), 125–131.
Horton, D.A., Bourne, G.T., Coughlan, J., Kaiser, S.M., Jacobs, C.M., Jones, A., et al.
(2008). Cyclic tetrapeptides via the ring contraction strategy: chemical techniques useful
for their identification. Organic and Biomolecular Chemistry, 6(8), 1386–1395.
Lebrihi, A., Errakhi, R., & Barakate, M. (2008). Nouvelle souche Streptomyces barakatei, ses
compose´s actifs de´rive´s et leur utilisation dans le traitement des plantes. Patent deposed:
INP/AGRONUTRITION, FR08 54053.
Lee, D.S. (2000). Dibutyl Phthalate, an -glucosidase Inhibitor from Streptomyces
melanosporofaciens. Journal of Bioscience and Bioengineering, 89(3), 271–273.
Lee, K.H., Kim, J.H., Lim, D.S., & Kim, C.H. (2000). Anti-leukaemic and anti-mutagenic
effects of di(2-ethylhexyl)phthalate isolated from Aloe vera Linne. The Journal of
Pharmacy and Pharmacology, 52(5), 593–598.
Magyar, A., Zhang, X., Abdi, F., Kohn, H., & Widger, W. (1999). Identifying the
bicyclomycin binding domain through biochemical analysis of antibiotic-resistant rho
proteins. The Journal of Biological Chemistry, 274(11), 7316–7324.
Makhija, S.N., & Vavia, P.R. (2003). Controlled porosity osmotic pump-based controlled
release systems of pseudoephedrine. I. Cellulose acetate as a semipermeable membrane.
Journal of Controlled Release, 89(1), 5–18.
Marchetti, L., Sabbieti, M.G., Menghi, M., Materazzi, S., Hurley, M.M., & Manghi, G.
(2002). Effect of phthatate esters on actin cytoskeleton of Py1a rat osteoblasts.
Histology and Histopathology, 17(4), 1061–1066.
Miyadoh, S. (1993). Research on antibiotic screening in Japan over the last decade: a
producing microorganism approach. Actinomycetologica, 7(2), 100–106.
Okada, T., Tanaka, K., Nakatani, F., Sakimura, R., Matsunobu, T., Li, X., et al. (2006).
Involvement of p-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily
of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing’s
sarcoma cells. International Journal of Cancer, 118(1), 90–97.
Rhee, K.H. (2002). Isolation and characterization of Streptomyces sp. KH-614 producing anti-
VRE (vancomycin-resistant enterococci) antibiotics. The Journal of General and Applied
Microbiology, 48(6), 321–327.
Roy, R.N., Laskar, S., & Sen, S.K. (2006). Dibutyl phthalate, the bioactive compound
produced by Streptomyces albidoflavus 321.2. Microbiological Research, 161(2),
121–126.
Sasaki, Y., Akutsu, Y., Matsui, M., Suzuki, K., Sakurada, S., Sato, T., et al. (1982). Studies
on analgesic oligopeptides. II. Structure-activity relationship among thirty analogs
of a cyclic dipeptide, cyclo(-Tyr-Arg-). Chemical & Pharmaceutical Bulletin, 30(12),
4435–4443.
Tanaka, Y.T., & Mura, S.O. (1993). Agro active compounds of microbial origin. Annual
Review of Microbiology, 47, 57–87.
Tatsuta, K., Tsuchiya, T., Umezawa, S., Naganawa, H., & Umezawa, H. (1972). Revised
structure for arglecin. The Journal of antibiotics, 25(11), 674–676.
Williams, S.T., Goodfellow, M., Alderson, G., Wllington, E.M., Sneath, P.H., & Sackin, M.J.
(1983). Numerical classification of Streptomyces and other related genera. Journal of
General Microbiology, 129(6), 1743–1813.
Yuan, F.S., Guo, S.L., Qin, Z.X., Deng, S.H., & Huang, G.H. (2001). Effect of dibutyl
phthalate on demodicidosis. Chinese Journal of Parasitology and Parasitic Diseases,
19(3), 160–162.
